Menu Search
Equities

Sartorius Stedim Biotech SA

DIM:PAR

Sartorius Stedim Biotech SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)176.95
  • Today's Change1.95 / 1.11%
  • Shares traded7.78k
  • 1 Year change-13.00%
  • Beta0.4176
Data delayed at least 15 minutes, as of Nov 25 2024 11:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform8
Hold5
Sell0
Strong Sell1

Share price forecast in EUR

The 15 analysts offering 12 month price targets for Sartorius Stedim Biotech SA have a median target of 218.00, with a high estimate of 310.00 and a low estimate of 134.00. The median estimate represents a 24.57% increase from the last price of 175.00.
High77.1%310.00
Med24.6%218.00
Low-23.4%134.00

Dividends in EUR

In 2023, Sartorius Stedim Biotech SA reported a dividend of 0.69 EUR, which represents a 52.08% decrease from last year. The 13 analysts covering the company expect dividends of 0.59 EUR for the upcoming fiscal year, a decrease of 14.49%.
Div growth (TTM)-52.08%
More ▼

Earnings history & estimates in EUR

On Oct 17, 2024, Sartorius Stedim Biotech SA reported 3rd quarter 2024 earnings of 0.76 per share. This result was in line with the consensus of the 4 analysts following the company and under-performed last year's 3rd quarter results by 10.59%.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate-1.90%
Sartorius Stedim Biotech SA reported annual 2023 earnings of 4.19 per share on Jan 26, 2024.
Average growth rate+22.40%
More ▼

Revenue history & estimates in EUR

Sartorius Stedim Biotech S.A. had 3rd quarter 2024 revenues of 655.40m. This missed the 683.89m consensus estimate of the 4 analysts following the company. This was 9.74% below the prior year's 3rd quarter results.
Average growth rate-0.24%
Sartorius Stedim Biotech S.A. had revenues for the full year 2023 of 2.78bn. This was 20.53% below the prior year's results.
Average growth rate+21.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.